Please assess the completion status of the following clinical trial:

Trial Title: Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. meet DSM-IV diagnostic criteria for ADHD-combined type;~2. estimated IQ of 75 or higher;~3. agree to comply with the randomly assigned treatment condition;~4. enrolled in full time school at first grade level or higher; AND~5. have a primary teacher available to complete ratings for the entire study duration.~Exclusion Criteria:~1. current or past history of seizures (not including benign febrile seizures) or other neurological disorders;~2. physical conditions that preclude administration of Strattera or other medical illness that might confound study results or increase the safety risk to subjects exposed to study treatments (i.e. marked cardiac conduction delay, etc.);~3. prior failed trial of Strattera defined as 3 weeks or more on a daily dose of Strattera of at least .8mg/kg or a documented inability to tolerate at least .8mg/kg/day;~4. serious forms of psychopathology other than ADHD, such autism, bipolar disorder, schizophrenia or any other psychopathology requiring urgent treatment with psychotropic medication; OR~5. children for whom discontinuation of their current psychotropic medication would represent a serious risk to themselves or others.~The presence of Oppositional Defiant Disorder (ODD), Conduct Disorder (CD) or learning disabilities will not result in exclusion from the study as they are commonly occurring comorbidities that have not been found to moderate response to ADHD treatments (Jensen et al., 2001). Enrollment in special education services will also not be an exclusionary criteria as work by this research group has found that such services do not affect response to ADHD treatments (Niemic, Fabiano, Pelham, \& Fuller, 2002).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Combined therapy (Type: EXPERIMENTAL): atomoxetine plus behavior therapy
- Drug therapy (Type: ACTIVE_COMPARATOR): atomoxetine alone

Based on this trial design, predict the completion outcome and termination type (if applicable).